MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.55, $1,100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
MANGOCEUTICALS, INC. signed a big deal and sold some stock, filing it all on 9/2.
AI Summary
On August 26, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on September 2, 2025.
Why It Matters
This 8-K filing indicates MANGOCEUTICALS, INC. has entered into a significant agreement and has engaged in equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- August 26, 2025 (date) — Date of Earliest Event Reported
- September 2, 2025 (date) — Filing Date
- 15110 N. Dallas Parkway , Suite 600 Dallas , Texas 75248 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did MANGOCEUTICALS, INC. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on August 26, 2025.
What was the purpose of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities but does not provide details on the purpose or the specific securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 26, 2025.
What is MANGOCEUTICALS, INC.'s principal executive office address?
The principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What are the key items reported in this 8-K filing?
The key items reported are the entry into a material definitive agreement, unregistered sales of equity securities, and financial statements and exhibits.
Filing Stats: 762 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-09-02 16:30:57
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $1.55 — cted common stock from the Company, for $1.55 per share, or a total of $1,100,000. Th
- $1,100,000 — any, for $1.55 per share, or a total of $1,100,000. The Subscription Agreements included c
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 253KB
- 0001493152-25-012557.txt ( ) — 500KB
- mgrx-20250826.xsd (EX-101.SCH) — 3KB
- mgrx-20250826_lab.xml (EX-101.LAB) — 33KB
- mgrx-20250826_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: September 2, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer